

DBV Technologies welcomes Mr. Stef Koppelman as its new General Scientific Advisor

BAGNEUX, France, July 19, 2012 - DBV Technologies (Euronext: DBV – ISIN: FR0010417345), creator of Viaskin®, a new standard in the treatment of allergy, announced today the appointment of Mr. Stef Koppelman, PhD as General Scientific Advisor. As such, Stef will champion DBV's research efforts and provide the Executive Committee with key advice and insight, notably on food allergens and scientific matters.

Stef Koppelman said: *"I am proud to join DBV Technologies as General Scientific Advisor. The Company has shown to be very vigorous in its development programs, and I am excited to contribute to that. My background in R&D at HAL Allergy, as well as my work for the University of Nebraska match well with the ambition of DBV to grow the company and strengthen the R&D activities. ."*



Pierre-Henri Benhamou, M.D., Chairman and CEO of DBV, said: *"The addition of Stef Koppelman, a worldwide recognized expert in food allergy, to DBV's R&D team will allow the company to improve and accelerate its scientific development. With Stef now on board and a fully staffed management team, we can focus both on the execution of our intense clinical development, and the maximization of the potentialities of the Viaskin technology platform."*

Prior to joining DBV Technologies, Stef Koppelman was R&D Director of HAL Allergy in the Netherlands where he took the lead for developing new immunotherapy products to treat food allergies. In the six years he spent at HAL Allergy, he implemented new techniques for protein characterization and modification, enabling the development of second-generation immunotherapy products. Since 2008, he holds a courtesy position as full professor at the University of Nebraska (USA), serving the Food Allergy Research and Resources Program (FARRP). Stef Koppelman is biochemist by training and took his PhD at the University Medical Centre in Utrecht (the Netherlands) in 1995. He worked for nine years at TNO, a Dutch-based science institute serving both governmental and commercial parties, and he was guest lecturer at the Department of Dermatology/Allergology of the University Medical Centre in Utrecht (NL) from 2000 till 2005. He has over 50 peer-reviewed papers on protein characterization, allergy and immunology, and assay development, including some reports in high-rated journals like the New England Journal of Medicine and the Lancet. He is inventor of several patents, was editor of a handbook on the development of immunochemical assays for quantification of food allergens, and has presented his work on numerous congresses.

About DBV Technologies:

DBV Technologies is opening up a decisive new approach to the treatment of allergy – a major public health issue that is constantly increasing in prevalence. Food allergies represent a true handicap in everyday life for millions of people and thus constitute a major unmet medical need. DBV Technologies has developed a unique, proprietary, worldwide-patented technology for administering an allergen to intact skin and avoiding massive transfer to the blood. The Viaskin® technology combines efficacy and safety as part of a treatment that seeks to improve the patient's tolerability of peanut and thus considerably lower the risk of a systemic, allergic reaction in the event of accidental exposure to the allergen. The company's significant development program has taken this revolutionary method through to the industrial stage in Europe, initially. The product's clinically proven safety of use enables the application of effective desensitization techniques (the efficacy of which is acknowledged worldwide) in the most severe forms of the allergy. DBV Technologies is focusing on food allergies (milk and peanut) for which there are currently no effective treatments. It has developed two products: Viaskin® Peanut and Viaskin® Milk. The developmental clinical program for Viaskin® Peanut has received Fast Track designation from the US Food and Drug Administration. The company will subsequently develop a Viaskin® patch for young children with house dust mite allergy – a true public health issue because this pathology is one of the main risk factors for childhood asthma. DBV Technologies shares are traded on segment C of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345). For more information on DBV Technologies, please visit our website: www.dbv-technologies.com.

CAUTION: Viaskin® is not approved for sale in the USA.



Contacts

David Schilansky

Chief Financial Officer

DBV Technologies

Tél. : +33(0)1 55 42 78 75

david.schilansky@dbv-technologies.com

NewCap.

Financial Communication and investor relations

Emmanuel Huynh / Alexandra Schiltz

Tél. : +33(0)1 44 71 94 94

dbv@newcap.fr

Ronald Trahan, APR

Press relations

Ronald Trahan

Tél. : +1 508 359 4005

rctrahan@ronaldtrahan.com